DOCSLIB.ORG

ID Week Poster 2015.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ID Week Poster 2015.Pdf Comparative Effectiveness of Cloxacillin/Cefazolin versus Vancomycin Empiric Therapy for Methicillin-susceptible Staphylococcus aureus (MSSA) Bacteremia Davie Wong MD1, Titus Wong MD2, Marc Romney MD2, Victor Leung MD2 1. Infectious Diseases Residency Training Program PGY-5, University of British Columbia, Vancouver, Canada. 2. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. INTRODUCTION RESULTS RESULTS Staphylococcus aureus is the leading cause of bacteremia and Table 1: Baseline characteristics and clinical outcomes of patients with methicillin-susceptible S. aureus bacteremia. carries a mortality of 20-30% [1]. Empiric vancomycin is Patient characteristics β-lactam (n=131) Vancomycin (n=124) P-value commonly prescribed for patients with S. aureus bacteremia Age (years) 53.2 ± 16.5 59.4 ± 18.3 0.005 (SAB) to cover methicillin-resistant S. aureus (MRSA) as up to Community-onset 108 (82.4) 88 (71.0) 0.03 50-60% of bloodstream isolates are methicillin-resistant at some centres [2,3]. Charlson comorbidity index 3 (1.0-6.0) 4 (1.0-7.0) 0.001 Infectious diseases consultation 98 (74.8) 80 (64.5) 0.07 However, vancomycin is inferior to semi-synthetic anti- Infective endocarditis 24 (18.3) 12 (9.7) 0.05 Staphylococcal penicillins and first generation cephalosporins for the treatment of methicillin-susceptible Staphylococcus aureus Surgical source control 33 (25.2) 19 (15.3) 0.05 (MSSA) bacteremia [4]. Vancomycin is associated with higher Empiric antimicrobials rates of infection-related mortality, re-infection and bacteriologic Vancomycin 88 (67.2) 123 (99.2) <0.001 failure compared to cloxacillin or cefazolin in the definitive Cloxacillin or cefazolin 131 (100.0) 0 (0.0) <0.001 treatment of MSSA bacteremia [4,5]. 3rd generation cephalosporin 40 (30.5) 0 (0.0) <0.001 Early studies suggested that empiric vancomycin may be inferior Piperacillin-tazobactam 33 (25.2) 0 (0.0) <0.001 to empiric β-lactam [2,6,7]. Although controversial, some experts Other 47 (35.9) 66 (53.2) 0.01 recommend empiric combination therapy with vancomycin plus Duration of empiric therapy (hours) 54 (42.0-69.0) 48 (29.6-75.8) 0.28 Figure 1: Patient enrollment process. Abbreviations: MSSA, cloxacillin or cefazolin for patients at the highest risk of Duration of definitive therapy (days) 31.5 (13.0-42.0) 28 (10.0-42.0) 0.17 methicillin-susceptible S. aureus; BSI, bloodstream infection. morbidity and mortality from SAB [8]. However, no studies have Time to receipt of empiric therapy (hours) 2 (0-7) 20.9 (4.2-28.3) <0.001 directly compared cloxacillin or cefazolin to vancomycin as CONCLUSIONS empiric therapy for patients with MSSA bacteremia who are Time to receipt of β-lactam (hours) 3.00 (0.2-16.3) 68.2 (51.5-95.4) <0.001 transitioned to cloxacillin or cefazolin as definitive therapy. We Time to receipt of cloxacillin or cefazolin (hours) 21.0 (4.4-31.2) 68.3 (51.6-95.4) <0.001 Empiric therapy with cloxacillin or cefazolin was associated with assessed if empiric cloxacillin or cefazolin compared to earlier clearance of bacteremia by a median of 1 day compared to vancomycin was associated with differences in survival and Primary outcome vancomycin, but was not associated with a difference in all-cause microbiological cure in this patient population. 28-day mortality 7 (5.3) 11 (8.9) 0.27 mortality in patients with MSSA bacteremia. Vancomycin Secondary outcomes monotherapy for the empirical treatment of MSSA bacteremia 90-day mortality 14 (10.7) 22 (17.7) 0.11 may be appropriate if definitive therapy with cloxacillin or MATERIALS & METHODS cefazolin can be initiated within 3 days. Duration of bacteremia (hours) 70.7 (46.9-119) 97.1 (61.6-148) 0.007 We performed a retrospective cohort study of adult inpatients ≥ 3 days 58 (50) 72 (63.2) 0.047 REFERENCES with their first episode of MSSA bacteremia at two tertiary care Hospital length of stay (days) 19 (12-41) 22.5 (13-46.5) 0.16 hospitals in Vancouver, Canada, between January 2007 and 1. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al. Clinical management of December 2014, inclusive. Consecutive patients were included if Staphylococcus aureus bacteraemia. Lancet Infect Dis 2011; 11: 208-222. Table 2: Outcome analysis comparing β-lactam versus vancomycin group, adjusted for predefined confounding variables. Abbreviations: they received cloxacillin or cefazolin for definitive therapy. 2. Khatib R, Saeed S, Sharma M et al. Impact of initial antibiotic choice and OR, odds ratio; CI, confidence interval. delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Patients were excluded if there was missing data for 28-day Eur J Clin Microbiol Infect Dis 2006; 25: 181-185. Outcomes Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value mortality, no empiric therapy was administered, death occurred 3. David MZ, Daum RS. Community-Associated Methicillin-Resistant within 24 hours following diagnosis of bacteremia, or 28-day mortality 0.58 (0.22-1.55) 0.28 1.03 (0.29-3.63) 0.96 Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging polymicrobial bacteremia. 90-day mortality 0.56 (0.27-1.14) 0.11 1.02 (0.40-2.60) 0.97 Epidemic. Clin Microbiol Rev 2010; 23: 616-687. 4. Kim SH, Kim KH, Kim HB et al. Outcome of Vancomycin Treatment in Patients The primary outcome was 28-day mortality. Secondary outcomes Ratio of Mean (95% CI) P-value Adjusted Ratio of Mean (95% CI) P-value with Methicillin-Susceptible Staphylococcus aureus Bacteremia. Antimicrob Agents were 90-day mortality, duration of bacteremia and hospital Duration of bacteremia 0.77 (0.64-0.93) 0.01 0.78 (0.63-0.97) 0.02 Chemother 2008; 52: 192-197. length-of-stay. Hospital length-of-stay 0.85 (0.68-1.07) 0.16 0.86 (0.68-1.08) 0.20 5. 15. McDanel JS, Perencevich EN, Diekema DJ et al. Comparative Effectiveness of Beta-lactams versus Vancomycin for Treatment of Methicillin-Susceptible Logistic regression methods were used to model the odds ratio of Staphylococcus aureus Bloodstream Infections among 122 Hospitals. Clin Infect death in the β-lactam compared to vancomycin group. Linear RESULTS Dis 2015; 61: 361-367 6. Schweizer ML, Furuno JP, Harris AD et al. Comparative effectiveness of nafcillin regression model was conducted for hospital length-of-stay and or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus duration of bacteremia. All models were adjusted for pre- The most common sources of bacteremia were unknown (27.1%), Rifampin and aminoglycosides were added for synergy in patients bacteremia. BMC Infect Dis 2011; 11: 279. specified confounding variables including age, sex, age-adjusted skin and soft tissue infections (18.4%), peripheral or central venous with prosthetic valve infective endocarditis or prosthetic joint 7. Lodise TP Jr., McKinnon PS, Levine DP, Rybak MJ. Impact of Empirical- Charlson-comorbidity index, Pitt bacteremia score, infectious catheters (16.5%) and injection drug use (15.7%). The prevalence infections. Fluoroquinolones, macrolides, trimethoprim- Therapy Selection on Outcomes of Intravenous Drug Users with Infective of infective endocarditis (IE) was 14.1%. Among patients with IE, sulfamethoxazole, and clindamycin were used for either treatment Endocarditis Caused by MSSA. Antimicrob Agents Chemother 2007; 51: 3731- diseases consultation, infective endocarditis and time to receipt 3733. 28-day and 90-day mortality was 2 (1.53%) and 3 (2.29%) in the β- of non-bacteremic co-infections or prophylaxis for other medical of empiric antibiotics. 8. McConeghy KW, Bleasdale SC, Rodvold KA. The Empirical Combination of lactam group and 0 and 1 (0.81%) in the vancomycin group. conditions. Vancomycin and a β-Lactam for Staphylococcal Bacteremia. Clin Infect Dis 2013; 57: 1760-1765. RESEARCH POSTER PRESENTATION DESIGN © 2015 www.PosterPresentations.com .
Load more

Recommended publications
  • Synergistic Activity of Ampicillin and Cloxacillin
    144 THE JOURNAL OF ANTIBIOTICS APR. 1969 SYNERGISTIC ACTIVITY OF AMPICILLIN AND CLOXACILLIN PROTECTIVE EFFECT OF CLOXACILLIN ON ENZYMATIC DEGRADATION OF AMPICILLIN BY PENICILLINASE, AND THERAPEUTIC ACTIVITY OF MIXTURES OF AMPICILLIN AND CLOXACILLIN MlNORUNlSHIDA, YASUHIROMlNE Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan and Shogo Kuwahara Department of Microbiology, Toho University School of Medicine, Tokyo, Japan (Received for publication February 15, 1969) A mixture of ampicillin (aminobenzyl penicillin, AB-PC) and cloxacillin (methylchlorophenylisoxazolyl penicillin, MCI-PC) showed an excellent bacteri- cidal activity even at low concentrations in which either of the penicillins alone did not have any activity against a clinically isolated strain of Escherichia colt, resistant to both of these penicillins. In this case, the microbial degrada- ion of AB-PC, caused by penicillinase (PC-ase), was strongly inhibited in the presence of MCI-PC. The enzymatic hydrolysis of AB-PC by extracellular nd cell-bound PC-ase, obtained from an AB-PC resistant strain of Staphylo- coccus aureus, was also inhibited in the presence of MCI-PC. Against that, t a under comparable conditions, penicillin G (PC-G) was almost completely destroyed by cell-bound PC-ase from this organism. An in vivo synergism was observed when mixtures of AB-PC and MCI-PC were applied for the treatment of mice challenged with a clinically isolated strain of E. coli resistant to both of these penicillins. Similar results were obtained in the treatment of mice experimentally infected with a strain of Staphylococcus aureus, which is highly resistant to AB-PC, but sensitive to MCI-PC. A decrease in the rate of hydrolysis of methicillin (dimethoxyphenyl penicillin, DMP-PC) by staphylococcal penicillinase (PC-ase) was first noted by Rolinson and his co-workers^.
    [Show full text]
  • Orbenin-DC® (Benzathine Cloxacillin)
    ORBENIN-DC- cloxacillin benzathine suspension Merck Sharp & Dohme Corp. ---------- Orbenin-DC® (benzathine cloxacillin) F-27865909 DRY COW (VACA SECA) Intramammary Infusion (Infusión intramamaria) LONG ACTING FORMULA (FÓRMULA DE LARGA ACCIÓN) CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION: Orbenin-DC (benzathine cloxacillin) is a stable, nonirritating suspension of benzathine cloxacillin containing the equivalent of 500 mg of cloxacillin per disposable syringe. Orbenin-DC is manufactured by a nonsterilizing process. Benzathine cloxacillin is a semisynthetic penicillin derived from the penicillin nucleus, 6-amino- penicillanic acid. Benzathine cloxacillin is the benzathine salt of 6-[3-(2-chlorophenyl)-5- methylisoxazolyl-4-carboxamido] penicillanic acid. The low solubility of Orbenin-DC results in an extended period of activity. Therefore, directions for use should be followed explicitly. ACTION: Benzathine cloxacillin is bactericidal in action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. It is active against gram-positive organisms associated with mastitis such as Staphylococcus aureus and Streptococcus agalactiae and, because of its resistance to penicillinase, penicillin G-resistant staphylococci which may be the cause of mastitis. Appropriate laboratory tests should be conducted, including in vitro culturing and susceptibility tests on pretreatment milk samples collected aseptically. SUSCEPTIBILITY TEST: The Kirby-Bauer1 procedure, utilizing antibiotic susceptibility disks, is a quantitative method that may be adapted to determining the sensitivity of bacteria in milk to Orbenin-DC. For testing the effectiveness of Orbenin-DC in milk, follow the Kirby-Bauer procedure using the 1 mcg oxacillin susceptibility disk.
    [Show full text]
  • Management of Penicillin and Beta-Lactam Allergy
    Management of Penicillin and Beta-Lactam Allergy (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Key Points • Beta-lactams are generally safe; allergic and adverse drug reactions are over diagnosed and over reported • Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam • The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed • Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances1 • For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similar core structure and/or major/minor antigenic determinants, use not recommended without desensitization • For type-1 immediate hypersensitivity reactions, cross-reactivity between penicillins (table 1) and cephalosporins is due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains • Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm,
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • Antibiotic Dosing for Children: Draft Expert Recommendations for the 2017 Essential Medicines List for Children (Emlc)
    Antibiotic Dosing for Children: Draft expert Recommendations for the 2017 Essential Medicines List for Children (EMLc) Purpose and Scope of Recommendations Expert recommendations for antibiotic dosing in the EMLc have been developed to address the lack of harmony in currently available international formularies. In many instances, recommendations are historical practise-based and not strongly evidence-based. Limited evidence is available from studies of effectiveness and safety as well as all age pharmacokinetics for children. National preferences for weight-based (US), age-banded (UK) and weight-banded (WHO) dosing strategies have resulted in quite widely varying recommendations. The rationale of this dosing guidance has been to provide simple recommendations which are feasible in the LMIC context. Dosing guidance has been given as a single total daily dose (mg/kg/day) with options for acceptable frequency of dosing which can be adapted to local context. A maximum upper dose has been provided, largely based on available adult dosing. These recommendations have been developed for children ages 2 months to 12 years. In general, the aim was to produce a simple dosing guidance that covered all clinical infection syndromes, except severe infections such as meningitis, where significantly higher doses are recommended. Dosing recommendations have not been adjusted for children with renal or liver impairment. The recommendations have not accounted for global variation in rates of antimicrobial resistance. Using a single dose in this overall guidance does not reflect the range of doses that are actually required to translate the guidance into practical weight/age based formulations for children. Methods For the development of these recommendations, the expert group comprised paediatricians, paediatric clinical pharmacologists and pharmacists based in the UK and Europe.
    [Show full text]
  • Guide Cellulite Adulte WEB EN.Pdf
    OCTOBER 2017 DRUG ANTIBIOTICS CELLULITIS IN ADULTS This optimal usage guide is mainly intended for primary care health professionnals. It is provided for information purposes only and should not replace the clinician’s judgement. The recommendations were developed using a systematic approach and are supported by the scientific literature and the knowledge and experience of Quebec clinicians and experts. For more details, go to inesss.qc.ca. GENERAL INFORMATION IMPORTANT CONSIDERATIONS Cellulitis can be observed on all skin surfaces, but most cases are found on the legs. CELLULITIS IN ADULTS Cellulitis is typically caused by β-hemolytic streptococci or Staphylococcus aureus, although a pathogen is isolated in less than 20 % of cases. Differential diagnosis is a major issue, since some skin conditions – that do not require antibiotic therapy – can present similar symptoms/signs. RISK FACTORS FOR DEVELOPING CELLULITIS Portal of entry or potential reservoir Comorbidities and other factors • Injury • Venous or arterial insufficiency • Skin problem (e.g., eczema) • Lymphedema • Toe web abnormalities (e.g., tinea pedis) • Uncontrolled diabetes • Hygiene or neglect issues • Immunosuppression • Uncorrected dental problem • History of cellulitis DIAGNOSIS SIGNS AND SYMPTOMS Photos available to help with diagnosis Cellulitis diagnosis is generally characterized by the acute appearance of a continuous erythematous area (without an area of healthy skin inside) that’s edematous, warm and painful. The patient may also have systemic symptoms (fever, nausea, vomiting, chills, malaise, lack of appetite). Cellulitis generally does not cause any epidermal changes (scales, scabs, vesicles, etc.). If such changes are present, suspect a different or related pathology (e.g., eczema). CLINICAL ASSESSMENT Assess the general condition of the patient.
    [Show full text]
  • ABX-2 Newslet: Cystitis & Skin
    Antibiotics & Common Infections ABX-2: Uncomplicated Cystitis & Skin Stewardship, Effectiveness, Safety & Clinical Pearls- April 2017 ABX-2 RELATED LINKS RxFILES ACADEMIC DETAILING ON ABX CANADIAN GUIDELINES/REFERENCES We are excited to bring out the ABX-2 topic on the treatment of uncomplicated cystitis Bugs & Drugs: and skin & soft tissue (SSTI) infections. The new charts in this newsletter will support http://www.bugsanddrugs.ca/ our spring academic detailing discussions with providers in Saskatchewan. Our MUMS Guidelines: discussions on ABX-1 were very well received and we know many of you made use of the http://www.mumshealth.com extra support tools such as the “Gone Viral?” office/clinic posters and the patient friendly “Viral Prescription Pad”. These are all available at www.RxFiles.ca/abx. CYSTITIS / UTI U.S. IDSA 2010: ABX-2: A FEW PEARLS FROM INSIDE THAT CAUGHT OUR EYE... Acute Uncomplicated Cystitis and Pylonephritis (UTI) UNCOMPLICATED CYSTISIS - Page 2 - 3 > 60 YEARS https://academic.oup.com/cid/article- lookup/52/5/e103 1) Staying Power: > 60 years & still 96% or better! Susceptibility of E. coli, the most common urinary pathogen, to nitrofurantoin SK MOH 2013: (MACROBID) remains at 96% or better in Saskatchewan (per recent antibiograms). UTI in Continuing Care Settings “I used to be https://saskpic.ipac-canada.org/ so strong...” STAYING POWER photos/custom/UTI%20Guidelines%20 2) 60% - Are you kidding?! 19April2013.pdf In some institutional settings, like long-term care, E. coli resistance to ciprofloxacin can be as high as ~60%. No wonder antimicrobial SOGC 2010: stewardship messaging suggests “Reserve to Preserve” for when we really Recurrent UTI C IPROFLOXAC I N need it! http://www.jogc.com/article/S1701- 2163(16)34717-X/pdf 3) Urine cultures are not required - for most Skip the Urine Req.
    [Show full text]
  • Effectiveness of Antibiotic Infusion at Drying-Off in Preventing New
    Effectiveness of Antibiotic Infusion Association Practitioners; Bovine open ofaccess distribution. American Copyright © at Drying-Off in Preventing New Mastitis Infections in Cows* M. G. Sinkevich, M.S., P. B. Barto, V.M.D., M.S., Ph.D., L. J. Bush, M.S., Ph.D. M. E. Wells, M.S., Ph.D. and G. D. Adams, M.S. Agricultural Experiment Station Oklahoma State University Stillwater, Oklahoma 74074 Bovine mastitis is responsible for greater Ayrshire, 13 Guernseys, 23 Jerseys, and 77 economic loss than any other single disease Holsteins) were blocked on the basis of number of affecting dairy cattle. Losses may be attributed to lactations completed (one, two, three or more) and reduced milk yield, altered milk composition, randomly assigned to treatment groups. Micro­ veterinary fees, cost of drugs, increased culling rate cocci, diphtheroids, and Staph, epidermidis were and cost of replacement cows (8). recorded as nonpathogens. Cows having quarters Most mastitis causing bacteria (Staphylococcus with these organisms were regarded as negative and aureus, Streptococcus uberis, Strep, dysgalactiae, were included in the experiment. Pseudomonas aeruginosa, Escherichia coli, Kleb­ The treatments were: (a) control, no infusion siella species, and Cory neb acterium pyogenes) are and (b) intramammary infusion of 500 mg. widely distributed in the environment, so that benzathine cloxacillina into each quarter after the complete eradication appears to be impossible last milking of the lactation period. All cows in (1,7,5). Strep, agalactiae is limited to the mam­ both groups were teat dipped with an iodine mary gland with many opportunities existing for solution15 (10,000 ppm available iodine) once a day transfer from cow to cow.
    [Show full text]
  • Package Leaflet: Information for the Patient Cloxacillin Villerton Nordic A
    Package leaflet: Information for the patient Cloxacillin Villerton Nordic A/S 1 g powder for solution for injection/infusion Cloxacillin Villerton Nordic A/S 2 g powder for solution for injection/infusion cloxacillin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Cloxacillin Villerton Nordic A/S is and what it is used for 2. What you need to know before you use Cloxacillin Villerton Nordic A/S 3. How to use Cloxacillin Villerton Nordic A/S 4. Possible side effects 5. How to store Cloxacillin Villerton Nordic A/S 6. Contents of the pack and other information 1. What Cloxacillin Villerton Nordic A/S is and what it is used for Cloxacillin Villerton Nordic A/S contains the active substance cloxacillin, which is an antibiotic acting against bacterial infections. It prevents the bacteria to form normal cell wall. Without a cell wall the bacteria die quickly. Cloxacillin is used to treat infections caused by certain bacteria, particularly staphylococci, which creates an enzyme called beta-lactamase. This enzyme has the ability to break down penicillin.
    [Show full text]
  • Antibiotics & Common Infections
    Antibiotics & Common Infections Stewardship, Effectiveness, Safety & Clinical Pearls October 2016 ANTIMICROBIAL RELATED LINKS ANTIMICROBIAL STEWARDSHIP GETTING STRATEGIES TO WORK - REAL WORLD CANADIAN GUIDELINES There are world-wide efforts that look • Public, patient & provider education for strategies to deal with the challenge of over time to change expectations Bugs & Drugs (Alberta/BC): growing antimicrobial resistance. How can • Realistic appreciation for viral versus http://www.bugsanddrugs.ca/ we all work together to be stewards of this bacterial etiologies important, but limited resource? • Delayed prescriptions for select MUMS Guidelines – “Orange Book” conditions with instructions to fill only (Anti-infective Review Panel): SELECT ANTIBIOTIC RESISTANT if symptoms do not resolve or condition http://www.mumshealth.com PATHOGENS OF MAJOR CONCERN worsens. (Offer to those who value convenience.) PATIENT RESOURCES • methicillin-resistant Staphylococcus aureus (MRSA) • “It’s easy to prescribe antibiotics. It i Canadian Antibiotic Awareness: • multi-drug resistant Streptococcus takes time, energy & trust not to do so.” http://www.antibioticawareness.ca pneumonia (MRSP) Success lies in changing the culture & the which includes: • vancomycin-resistant enterococci (VRE) understanding of antibiotic limitations, • multi-drug resistant Escherichia coli & benefits & harms. 1. Viral Prescription Pad for respiratory other gram negative bacteria (e.g. ESBL) infections (download or order for free); ANTIBIOTIC HARMS – UNDERAPPRECIATED provides information about symptomatic KEY STRATEGIES FOR REDUCING ANTIBIOTICS Q To the Patient relief for viral infections and indicates when • vaccinations to prevent infections and • 1 in 5 emergency room visits for adverse patients should consider a return visit. decrease antibiotic use drug events (ADEs) are from antibiotics. • practice and educate on infection • Antibiotics are the most common cause of 2.
    [Show full text]
  • Summary Report
    European Medicines Agency Veterinary Medicines and Inspections Revision 11 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS PENICILLINS SUMMARY REPORT 1. Penicillins (and their salts including the benzatine, procaine and sodium salts) have been widely used in veterinary medicine for more than 30 years and today form the most important group of antibiotics. 2. Penicillins have a low toxicity in the normal sense of the word; the therapeutic index is more than 100, and toxic effect have only been seen after extremely high doses. No teratogenic effects have been recorded. In connection with therapeutic use of penicillins hypersensitivity reactions are by far the most commonly encountered side-effects. The amount of penicillin haptene necessary to sensitize a subject is several orders of magnitude higher than the quantity needed to trigger an allergic reaction in an already sensitized individual. Furthermore, it takes a much higher oral dose to induce an allergic reaction than if the drug is administered parenterally. Against this background it can be concluded that the small amounts of penicillins which may be present in food products of animal origin are not able to sensitize the consumer, but will, at the most, trigger a reaction in already sensitized subjects. Literature contains only very few references reporting allergic reactions traceable to penicillin residues in foods. At least 6 µg penicillin (equivalent to 10 IU penicillin) seems normally necessary to provoke an allergic reaction. Penicillins are strong inhibitors of the bacteria used in production processes employed by the dairy industry. Concentrations as low as 0.006 µg (0.01 IU) penicillin per gram milk considerably inhibit starter cultures and delay acid production.
    [Show full text]
  • Efficacy of Cloxacillin Versus Cefazolin for Methicillin
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2018-023151 on 1 September 2018. Downloaded from Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non- inferiority trial Charles Burdet,1,2 Paul Loubet,1,3 Vincent Le Moing,4 William Vindrios,3 Marina Esposito-Farèse,5,6 Morgane Linard,2 Tristan Ferry,7 Laurent Massias,1,8 Pierre Tattevin,9 Michel Wolff,1,10 François Vandenesch,11 Nathalie Grall,1,12 Caroline Quintin,5 France Mentré,1,2 Xavier Duval,1,6 François-Xavier Lescure,1,3 for the CloCeBa study group To cite: Burdet C, Loubet P, ABSTRACT Strengths and limitations of this study Le Moing V, et al. Efficacy of Introduction Methicillin-susceptible Staphylococcus cloxacillin versus cefazolin aureus (MSSA) bacteraemia is a common and severe for methicillin-susceptible ► First randomised controlled trial to compare the disease responsible for approximately 65 000 deaths every Staphylococcus aureus safety and efficacy of cefazolin and cloxacillin for year in Europe. Intravenous antistaphylococcal penicillins bacteraemia (CloCeBa): treatment of methicillin-susceptible Staphylococcus (ASP) such as cloxacillin are the current recommended study protocol for a aureus bacteraemia. antibiotics. However, increasing reports of toxicity and randomised, controlled, non- ► Pragmatic trial designed to interfere as little as pos- recurrent stock-outs of ASP prompted healthcare providers inferiority trial. BMJ Open sible with usual care. 2018;8:e023151. doi:10.1136/ to seek for alternative antibiotic treatment. Based on ► Investigation of the potential impact of different bmjopen-2018-023151 retrospective studies, cefazolin, a first-generation types of S.
    [Show full text]